Evidence map›Paper›PMID 39865560›Full record

ArticleFuture oncology (London, England)2025

Evaluating patients on CDK-4/6 inhibitor treatment for differences in treatment according to demographic variables.

Sneha Rajendran, Marina Petruzzi, Dianxu Ren, Catherine Bender, Adam Brufsky, Margaret Q Rosenzweig

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sneha RajendranDepartment of Hematology/Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.ORCID 0000-0002-2351-9396
Marina PetruzziSchool of Medicine, Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania, USA.
Dianxu RenSchool of Nursing, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Catherine BenderSchool of Nursing, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Adam BrufskyDepartment of Hematology/Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Margaret Q RosenzweigSchool of Nursing, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe accessibility and outcomes of cyclin-dependent kinase 4 and 6 inhibitors (CDKi) in metastatic breast cancer (MBC) according to demographic factors are unknown. RESEARCH DESIGN AND

methodsRetrospective review of patients with ER+ MBC prescribed first-line CDKi therapy from January 2015 through December 2022. Abstraction included time from CDKi prescription to drug initiation (TTI), time from CDKi initiation to progression (TTP), time from CDKi initiation to death or 6/30/2022, and variables (age, race, partner status, insurance type, BMI, number of comorbidities). Descriptive, comparative, and correlational statistics are used.

results

conclusionsMedicaid insurance is associated with worse outcomes of MBC therapy, not attributed to TTI delay. Personalization of support may be helpful.

Indexed as

Breast NeoplasmsCyclin-Dependent Kinase 4Protein Kinase InhibitorsAdultAgedAged, 80 and overFemaleHumansMedicaidMiddle AgedRetrospective StudiesTreatment OutcomeUnited StatesCDK4 protein, humanCyclin-Dependent Kinase 4Protein Kinase InhibitorsBreastchemotherapymetastasisoutcomes researchwomen’s health

Identifiers

PMID39865560
PMCPMC11845102

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.